The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Cascone, Tina; Xu, Li; Lin, Heather Y; Liu, Wenbin; Tran, Hai T; Liu, Yuan; Howells, Kathryn; Haddad, Vincent; Hanrahan, Emer; Nilsson, Monique B; Cortez, Maria A; Giri, Uma; Kadara, Humam; Saigal, Babita; Park, Yun-Yong; Peng, Weiyi; Lee, Ju-Seog; Ryan, Anderson J; Jüergensmeier, Juliane M; Herbst, Roy S; Wang, Jing; Langley, Robert R; Wistuba, Ignacio I; Lee, Jack J; Heymach, John V

Cascone, Tina; Xu, Li; Lin, Heather Y; Liu, Wenbin; Tran, Hai T; Liu, Yuan; Howells, Kathryn; Haddad, Vincent; Hanrahan, Emer; Nilsson, Monique B; Cortez, Maria A; Giri, Uma; Kadara, Humam; Saigal, Babita; Park, Yun-Yong; Peng, Weiyi; Lee, Ju-Seog; Ryan, Anderson J; Jüergensmeier, Juliane M; Herbst, Roy S; Wang, Jing; Langley, Robert R; Wistuba, Ignacio I; Lee, Jack J; Heymach, John V.

Afiliação

Cascone T; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Xu L; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lin HY; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Liu W; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Tran HT; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Liu Y; GlaxoSmithKline, Research Triangle Park, North Carolina and Collegeville, Pennsylvania.
Howells K; AstraZeneca, Macclesfield, United Kingdom.
Haddad V; AstraZeneca, Macclesfield, United Kingdom.
Hanrahan E; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Nilsson MB; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cortez MA; Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Giri U; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kadara H; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Saigal B; Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut, Lebanon.
Park YY; Division of Cancer Medicine and Department of Thoracic and Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Peng W; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lee JS; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ryan AJ; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jüergensmeier JM; AstraZeneca, Macclesfield, United Kingdom.
Herbst RS; AstraZeneca, Macclesfield, United Kingdom.
Wang J; Section of Medical Oncology and Department of Developmental Therapeutics, Yale School of Medicine, New Haven, Connecticut.
Langley RR; Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Wistuba II; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lee JJ; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Heymach JV; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Clin Cancer Res ; 23(18): 5489-5501, 2017 Sep 15.

Article em En | MEDLINE | ID: mdl-28559461

Assuntos

Carcinoma Pulmonar de Células não Pequenas/metabolismo; Carcinoma Pulmonar de Células não Pequenas/patologia; Resistencia a Medicamentos Antineoplásicos; Fator de Crescimento de Hepatócito/metabolismo; Neoplasias Pulmonares/metabolismo; Neoplasias Pulmonares/patologia; Neovascularização Patológica/metabolismo; Proteínas Proto-Oncogênicas c-met/metabolismo; Transdução de Sinais; Animais; Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico; Carcinoma Pulmonar de Células não Pequenas/genética; Linhagem Celular Tumoral; Ensaios Clínicos Fase II como Assunto; Ensaios Clínicos Fase III como Assunto; Modelos Animais de Doenças; Resistencia a Medicamentos Antineoplásicos/efeitos dos fármacos; Perfilação da Expressão Gênica; Humanos; Hipóxia/genética; Hipóxia/metabolismo; Estimativa de Kaplan-Meier; Neoplasias Pulmonares/tratamento farmacológico; Neoplasias Pulmonares/genética; Masculino; Camundongos; Terapia de Alvo Molecular; Estudos Multicêntricos como Assunto; Neovascularização Patológica/genética; Prognóstico; Inibidores de Proteínas Quinases/farmacologia; Receptores de Fatores de Crescimento do Endotélio Vascular/antagonistas & inibidores; Ensaios Antitumorais Modelo de Xenoenxerto

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google